“Exciting news! $AKRO to share preliminary Week 96 topline results from the Phase 2b SYMMETRY study on #EFX for compensated cirrhosis (F4) due to #MASH. Big step forward in tackling liver disease! 🌟📊 Monday 8:00 AM ET. #Biotech #Innovation”
#AKRO #EFX #MASH #Biotech #Innovation